EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitMultizentrische Studie

Post‐Hematopoietic Stem Cell Transplantation Eczematous Dermatitis Spectrum Successfully Treated With Dupilumab: A Case Series and Review of the Literature

Belén Rodríguez-Sánchez iD, Minia Campos-Domínguez iD, Antonio Del Alcalá-Ramírez Del Puerto iD, José Bernabeu-Wittel, María Teresa Monserrat-García, Francisco Arias-Lotto, Veronica Parra-Blanco, Cristina Beléndez-Bieler, Marina García-Morín, Eduardo Bardón-Cancho iD, Jose Manuel Marco-Sánchez, Alba González-Gerrero und 2 weitere

Pediatric Dermatology · 2026-03 · 43 (2) · 289-299

DOI: 10.1111/pde.70084 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pediatric Dermatology, online erschienen am 20.11.2025. Verfasst von Belén Rodríguez-Sánchez und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Antibodies, Monoclonal, Humanized, Eczema, Graft vs Host Disease. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hematopoietic stem cell transplantation (HSCT) is associated with several dermatological adverse events, including the de novo onset of pruritus and eczema. Some authors consider this a variant of graft‐versus‐host disease (GvHD) and refer to it as eczematous or atopic dermatitis (AD)‐like GvHD, while others categorize it separately as eczematous or AD‐like dermatitis. This study aimed to report a pediatric case series and review previously published cases treated with dupilumab.

Methods

Retrospective multicenter study including patients aged 0–18 treated with dupilumab for new eczematous lesions following HSCT up to 2024 in three tertiary hospitals in Spain. A literature review in PubMed identified all reported pediatric and adult cases.

Results

A total of 24 cases were identified: 9 from our centers and 15 from the literature. Median onset was 3 months post‐HSCT. All patients presented with pruritus and eczema. 47% showed flexural involvement. Histology revealed eczematous features in 73%, mixed GvHD/eczema in 20%, and pure GvHD in 7%. 38% were classified as post‐HSCT eczema, and 63% as eczematous or AD‐like GvHD. All were refractory to topical corticoids and different systemic immunosuppressants. Dupilumab led to complete or near‐complete resolution in 96% of cases. No serious adverse events were reported.

Conclusion

Dupilumab appears to be effective and safe for eczematous lesions occurring after HSCT, regardless of whether the histopathological characteristics align with eczema or GvHD. This supports a shared spectrum between eczematous dermatitis and GvHD, and the use of a neutral diagnostic term. Further research is needed to clarify its pathogenesis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationAntibodies, Monoclonal, HumanizedEczemaGraft vs Host DiseaseHumansRetrospective StudiesMaleFemaleChildAdolescentChild, PreschoolInfantTreatment OutcomeInfant, Newborn

Stichwörter der Autor:innen

atopic dermatitisdupilumabgraft versus host diseasestem cell transplantation

Substanzen

dupilumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Dermatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
  • Department of Dermatology, Hospital Universitario Virgen del Rocío, Seville, Spain.
  • Department of Pathology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
  • Department of Pediatrics, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
  • Department of Dermatology, Hospital Sant Joan de Déu, Barcelona, Spain.

ORCID-Profile: Belén Rodríguez-Sánchez, Minia Campos-Domínguez, Antonio Del Alcalá-Ramírez Del Puerto, Eduardo Bardón-Cancho, Eulàlia Baselga-Torres

Zitieren

APA

Rodríguez-Sánchez, B., Campos-Domínguez, M., Del Alcalá-Ramírez Del Puerto, A., Bernabeu-Wittel, J., Monserrat-García, M. T., Arias-Lotto, F., Parra-Blanco, V., Beléndez-Bieler, C., García-Morín, M., Bardón-Cancho, E., Marco-Sánchez, J. M., González-Gerrero, A., Baselga-Torres, E., & Prat-Torres, C. (2026). Post‐Hematopoietic Stem Cell Transplantation Eczematous Dermatitis Spectrum Successfully Treated With Dupilumab: A Case Series and Review of the Literature. Pediatric Dermatology, 43(2), 289-299. https://doi.org/10.1111/pde.70084

Vancouver

Rodríguez-Sánchez B, Campos-Domínguez M, Del Alcalá-Ramírez Del Puerto A, Bernabeu-Wittel J, Monserrat-García MT, Arias-Lotto F, et al. Post‐Hematopoietic Stem Cell Transplantation Eczematous Dermatitis Spectrum Successfully Treated With Dupilumab: A Case Series and Review of the Literature. Pediatric Dermatology. 2026;43(2):289-299. doi:10.1111/pde.70084

BibTeX
@article{RodrguezSnchez2026,
  author = {Rodríguez-Sánchez, Belén and Campos-Domínguez, Minia and Del Alcalá-Ramírez Del Puerto, Antonio and Bernabeu-Wittel, José and Monserrat-García, María Teresa and Arias-Lotto, Francisco and Parra-Blanco, Veronica and Beléndez-Bieler, Cristina and García-Morín, Marina and Bardón-Cancho, Eduardo and Marco-Sánchez, Jose Manuel and González-Gerrero, Alba and Baselga-Torres, Eulàlia and Prat-Torres, Carolina},
  title = {Post‐Hematopoietic Stem Cell Transplantation Eczematous Dermatitis Spectrum Successfully Treated With Dupilumab: A Case Series and Review of the Literature},
  journal = {Pediatric Dermatology},
  year = {2026},
  volume = {43},
  number = {2},
  pages = {289--299},
  doi = {10.1111/pde.70084}
}
Kostenlos starten →